Integral Health Asset Management LLC Has $49.40 Million Holdings in Vera Therapeutics, Inc. $VERA

Integral Health Asset Management LLC raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 47.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,700,000 shares of the company’s stock after acquiring an additional 550,000 shares during the period. Vera Therapeutics accounts for about 3.3% of Integral Health Asset Management LLC’s portfolio, making the stock its 5th biggest position. Integral Health Asset Management LLC’s holdings in Vera Therapeutics were worth $49,402,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. UBS Group AG grew its stake in shares of Vera Therapeutics by 57.5% in the 3rd quarter. UBS Group AG now owns 162,075 shares of the company’s stock worth $4,710,000 after acquiring an additional 59,142 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Vera Therapeutics by 129.7% during the third quarter. BNP Paribas Financial Markets now owns 253,976 shares of the company’s stock valued at $7,381,000 after purchasing an additional 143,424 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of Vera Therapeutics during the third quarter valued at about $264,000. Legal & General Group Plc boosted its holdings in Vera Therapeutics by 1.7% during the third quarter. Legal & General Group Plc now owns 51,263 shares of the company’s stock worth $1,490,000 after purchasing an additional 845 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Vera Therapeutics by 10.7% during the third quarter. Russell Investments Group Ltd. now owns 163,169 shares of the company’s stock worth $4,742,000 after purchasing an additional 15,705 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $39.96 on Friday. The company has a market capitalization of $2.80 billion, a PE ratio of -8.58 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05. The company has a 50-day simple moving average of $43.81 and a 200 day simple moving average of $36.75.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter in the previous year, the firm posted ($0.72) EPS. On average, research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Wall Street Analyst Weigh In

VERA has been the subject of a number of recent analyst reports. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a research report on Friday, December 5th. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a research note on Wednesday. JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a report on Friday, December 19th. Evercore increased their price target on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.45.

Insider Buying and Selling

In other Vera Therapeutics news, insider William D. Turner sold 2,187 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the transaction, the insider directly owned 45,313 shares of the company’s stock, valued at approximately $1,902,239.74. This represents a 4.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sean Grant sold 4,949 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $207,759.02. Following the completion of the sale, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This represents a 4.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,490 shares of company stock worth $1,405,910 in the last three months. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.